



Cognizant  
Shared  
Investigator  
Platform

Cognizant® Shared Investigator Platform (SIP)

# Support for the “new normal” in the COVID-19 crisis

“..Travel restrictions, quarantine measures or the COVID-19 illness itself may require changes to policies and procedures.” The FDA identified the following specific areas of concern: “the informed consent process, study visits and procedures, data collection, study monitoring, adverse event reporting, and changes in investigator(s), site staff and/or monitor(s).” It recommends **“optimizing the use of central and remote monitoring programs to maintain oversight of clinical sites.”**

- FDA guidance on conducting clinical trials of medical products during COVID-19 pandemic, issued in early March 2020

The Shared Investigator  
Platform (SIP)  
**supports the “new  
normal” in the  
COVID-19 crisis**

## Contents

[Click a link below to jump to that section](#)

[COVID-19 changes clinical trial execution](#)

[Clinical operations adoption of remote monitoring](#)

[SIP enables a rapid transition to remote collaboration between sponsors and sites across the clinical trial life cycle](#)

[Currently supported remote clinical trial activities in SIP](#)

[Future SIP enhancements to effectively manage a trial in a post COVID-19 world](#)

[The end state: a SIP-connected clinical ecosystem](#)

## COVID-19 changes clinical trial execution

COVID-19 changed the world seemingly overnight. We went from “business as usual” to the “new normal” at warp speed. The impact of the pandemic will be felt by businesses across the globe for years to come. One of the industries experiencing the greatest impact is life sciences, particularly in the area of clinical trials.

In light of the new normal, the life sciences industry must pivot, transitioning from its traditional operating model to an accelerated, technology-enabled paradigm for drug development, clinical trials and regulatory approvals. To do that, the industry must leverage modern digital sciences and technologies to accelerate the development of new therapies and bring new, potentially life-saving treatments to market in record time.

When it comes to clinical trials, one thing has become abundantly clear in light of the COVID-19 pandemic—the traditional process of face-to-face visits and on-site monitoring needs to be reexamined. Widespread travel bans and health and safety guidelines, such as social distancing, has forced sponsors to find new ways to collaborate with trial sites.

With increasing pressure to accelerate drug development, enhance collaboration and reduce costs despite the challenges brought forth by the pandemic, many sponsors turned to the Cognizant Shared Investigator Platform (SIP), a robust tool that unites sponsors and clinical researchers.


SIP transforms how sponsors and sites collaborate throughout the clinical trial life cycle, providing a solution for streamlining clinical trial set up and execution, and resulting in improved investigator experiences and increased collaboration across the clinical ecosystem.

The adoption of digital work practices like those provided by the SIP platform enables life sciences companies to adapt in the face of current challenges and not only sustain, but accelerate, clinical trials. This move to modern trial technologies is transforming the industry, turning a disruption into a change for the better.

# Clinical operations adoption of remote monitoring

Traditional methods of conducting clinical trials have given way to new approaches in the COVID-19-altered world. Trial set up and execution have transitioned from in-person monitoring to remote, digital techniques that enable business to continue—and thrive—in today’s environment.

## Pre-COVID-19



Pharma clinical research associates (CRAs) / monitors travel three to four days per week visiting sites for pre-study, initiation, periodic monitoring and close-out visits.

Cost of site visits is approximately **\$1,069,670 per trial annually** with an additional \$42,700 per initiation visit.

## During COVID-19



CRAs / monitors and some staff are unable to travel to sites during the epidemic. Clinical trials must transition to remotely monitored pre-study, initiation, periodic and close-out visits.

**SIP is helping to enable the rapid transition to remote collaboration** between sponsors and sites across the clinical trial life cycle.

---

**E6-GCP does not require in-person visits, defining monitoring as** “The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded and reported in accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP) and the applicable regulatory requirement(s).”

# SIP enables a rapid transition to remote collaboration between sponsors and sites across the clinical trial life cycle

## PROTOCOL



Remote collaboration with data scientists, internal teams, key opinion leaders/potential sites




## SITE SELECTION



Remote management of trial site selection and activation tracking



## MANAGE & CONDUCT



Remote training with recorded or live sessions

Secure verification and distribution of documents

Automated document flow between sponsor electronic Trial Master File (eTMF) and electronic Investigator Site File (eISF)

Centralize communications, drug shipment addresses, Institutional Review Boards (IRBs) and lab information

Remote gathering of investigator feedback



## CLOSE-OUT



Remote, systematic management of study site/study close-out

Verification of close-out documentation

Virtual close-out visits

Investigator feedback collection at close-out



## RESULTS & REPORTS



Secure distribution of Clinical Study Report (CSR) and other reports and study results to sites

# Currently supported remote clinical trial activities in SIP

75,000+ clinical researchers and

18,500 sites are ready to support COVID-19 research and all other studies.



**Tasks and Delegation**  
Consolidates news, links and tasks across sponsors and studies.



**Survey**  
Facilitates response to feasibility and study surveys across all sponsors.



**User Profile**  
Includes sponsor searchable electronically signed "Digital CV."



**Payment API**  
Integrates alerts and dashboards for full cycle of payment tracking updates.



**Facility / Department Profile(s)**  
Describes the capabilities of each clinical location at which patients are treated.



**Training**  
Reduces redundant training by securing credit through MRT and tracks study training completion in one location.



**Organization Profile**  
Enables sites to proactively delegate SIP maintenance to the site support organizations with which they work, streamlining study start up.



**Document Exchange Study Start Up**  
Collaborates, exchanges and electronically signs study documents and streamlines study start up with Document Packages.



**Study Workspace**  
Gives sites access to all studies across all sponsors in a single location and eliminates data entry by enabling reuse of site details across studies.



**Safety Exchange**  
Leverages a single inbox across all SIP locations, reducing the time needed to review and acknowledge Safety Letters.



## Future SIP enhancements to effectively manage a trial in a post- COVID-19 world



### SIP Enhanced Communications

Schedule remote meetings between site users and monitors with video and teleconferencing capabilities. Track meeting agenda and action items from the meeting.



### Unified Digital Platform

Enable integration with other Cognizant assets, like Digital Protocol, along with other partner vendors to provide a unified digital platform.




### Expand SIP Partnerships

The SIP-connected clinical ecosystem is growing to include partnerships with leading eISF vendors, enabling the end-to-end flow of documents from eTMF to eISF via SIP.



# The end state: a SIP-connected clinical ecosystem

Uniting all stakeholders across clinical trials



## Future SIP Stakeholders Coming 2020-21

Clinical Research Orgs	Labs
Shared Investigator Platform	Medical Devices
Institutional Review Board	Regulatory Bodies

## Future Partners Coming 2020-21

Electronic Health Records  
RWE  
Genomic

---

## About Cognizant Life Sciences

Cognizant's Life Sciences business unit partners with biopharmaceutical and med-tech companies to develop strategies and apply solutions to healthcare challenges across the value chain. Our services and products, including the Shared Investigator Platform (SIP), are digitizing interactions between sponsors and investigators across every phase, helping the industry subtract time from clinical development and add it to patient lives. To learn more, visit [cognizant.com/life-sciences](https://cognizant.com/life-sciences).

---

## About Cognizant

Cognizant (Nasdaq-100: CTSI) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the U.S., Cognizant is ranked 194 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at [cognizant.com](https://cognizant.com) or follow us @Cognizant.

---

# Cognizant<sup>®</sup>

### World Headquarters

500 Frank W. Burr Blvd.  
Teaneck, NJ 07666 USA  
Phone: +1 201 801 0233  
Fax: +1 201 801 0243  
Toll Free: +1 888 937 3277

### European Headquarters

1 Kingdom Street  
Paddington Central  
London W2 6BD England  
Phone: +44 (0) 20 7297 7600  
Fax: +44 (0) 20 7121 0102

### India Operations Headquarters

#5/535 Old Mahabalipuram Road  
Okkiyam Pettai, Thoraiakkam  
Chennai, 600 096 India  
Phone: +91 (0) 44 4209 6000  
Fax: +91 (0) 44 4209 6060